← All trials
NCT03436576
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 12, 2018
- Primary completion
- Oct 19, 2018
- Completion date
- Nov 19, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Pontificia Universidad Catolica de ChileLead sponsor
- Pontificia Universidad Catolica de ChileOverall official - principal investigator
- Hospital Dr. Sótero del RíoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.